SavedAdd your journal

Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 0

Daptomycin Use in MRSA Bacteremia of a Patient with Myasthenia Gravis:A Case Report

Birsen Y. ARSLAN
Ergenekon KARAGÖZ
Ferhat ARSLAN
Pages
96–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we would like to share our experience about daptomycin use in Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia of a patient with myasthenia gravis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myasthenia gravis (MG) is the most common autoimmune disease affecting the neuromuscular junction and is characterized by ocular, bulbar, limb and respiratory muscle involvement.
📊
Key Findings & Data:Some of the drugs may induce and exacerbate MG.
💡
Conclusion & Impact:Herein, we would like to share our experience about daptomycin use in Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia of a patient with myasthenia gravis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Myasthenia gravis (MG) is the most common autoimmune disease affecting the neuromuscular junction and is characterized by ocular, bulbar, limb and respiratory muscle involvement. Some of the drugs may induce and exacerbate MG. Antibiotics are also one of the most important medication groups that may worsen MG and they should be used with caution in these patients with MG. Herein, we would like to share our experience about daptomycin use in Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia of a patient with myasthenia gravis.

🔖

Cite This Article

ARSLAN, B. Y., KARAGÖZ, E., ARSLAN, F. (2016). Daptomycin Use in MRSA Bacteremia of a Patient with Myasthenia Gravis:A Case Report. Medicine Science, Cilt: 5 - Sayı: 0, 96–98. https://ajindex.com/articles/277662

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Keesey, John C. Clinical evaluation and management of myasthenia gravis. Muscle & Nerve. 2004;29(4):484-505.
  2. Chaudhuri A, Behan PO. Myasthenic Crisis. QJM: 2009;102(2):97-107.
  3. Christopher JS, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the us fda adverse event reporting system and a literature review. Drug Safety: An International Journal of Medical Toxicology and Drug Experience. 2011;34:839-47.
  4. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009-15. Gould IM. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2011;66 Suppl 4:iv17-iv21.